On August 19, after the company announced a tender to monetize its data assets in order to raise income and increase profit, shares of Indian Railway Catering and Tourism Corporation (IRCTC) in...
ReNew Power announced a loss of Rs10.4 crore for the April–June quarter of FY23 on Friday as a result of some adjustments to one-time expenses. In comparison to a net profit of Rs 425 million...
IRB InvIT Fund announced that India Ratings and Research (Ind-Ra) has affirmed (IRB InvIT) senior debt rating at ‘IND AAA’. The rating agency affirms Outlook as ‘Stable’. Fur...
SBI accepted a haircut of over 58% off the total outstanding when selling the non-performing loan account of KSK Mahanadi Power Company to Aditya Birla ARC for Rs1,622 crore. As of April 2022, ...
Debt-ridden Future Enterprises Ltd (FEL) reported that it has missed two interest payments totaling Rs12.68 crore on non-convertible debentures. The payment was expected to be made by August 17...
TCM Ltd has informed to the exchanges regarding incorporation of a wholly owned subsidiary- TCM Properties Pvt Ltd. As per the regulatory filing, the said wholly owned subsidiary com...
Adani Ports and Special Economic Zone Limited is an India-based integrated ports and logistics company. The Company is primarily engaged in developing, operating and maintaining the ports services, ports-related infrastructure development activities and development...
Analysts at IIFL Securities cut their FY23/24 PAT estimates for upstream and downstream companies by 2-13%/4-15% respectively, to reflect Q1 performance, additional duties and auto fuel losses. The CGDs offer good growth visibility. If the weakness in oil and product cracks holds, OMCs could benefit.
Existing order book provides growth visibility for FY23-24. Fresh ordering will be keenly watched for moderation. IIFL Securities preferred picks include PNC, Ashoka Buildcon, KNRC, HGINFRA and GRINFRA (in that order).
High raw-material inflation, elevated freight expenses, and normalization in costs have impacted margins of Indian pharma players. During Q1FY23 EBITDA margins of 17 pharma stocks under IIFL Securities coverage universe declined on an average by ~450-500 basis points YoY.
Q1FY23 saw an aggregate PAT growth of 17% on a 3-year CAGR basis for a sample of 437 BSE 500 companies. Excluding financials and commodities, PAT growth was 15% on a 3-year CAGR.